3rd Apr 2009 16:41
Tepnel Life Sciences plc
("Tepnel" or the "Company")
Directors' Exercise of Options
The Company was informed on 3 April 2009 that today the following Directors, exercised options as detailed in the table below.
|
Name |
Number of Options exercised |
Exercise Price (pence) |
Number of Tepnel Shares held after the exercise of the options |
% of issued share capital |
|
IA Craig |
500,000 |
5.32 |
2,500,000 |
0.76 |
|
B Matzilevich |
11,500,000 |
* |
17,456,783 |
5.27 |
|
MK Slater |
1,950,000 |
Nil |
2,050,000 |
0.62 |
|
DR Marvin |
500,000 |
5.32 |
518,000 |
0.16 |
|
M Miller |
500,000 |
5.32 |
500,000 |
0.15 |
|
AJM Clark |
500,000 |
5.32 |
2,722,000 |
0.82 |
* 3,000,000 exercised at 6.125 pence per share and 8,500,000 exercised at Nil pence per share.
For further information:
Tepnel Life Sciences plc
Ben Matzilevich, Chief Executive Officer
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Joey Whinary
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark Percy
Tom Sheldon
Christopher Wren
Tel: +44 20 7107 8000
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services Group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. Tepnel focuses on these niche operations with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments. For more information please visit www.tepnel.com.
Related Shares:
TED.L